Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors

References

• Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15:1293 - 301; PMID: 11005253
   PubMed Web of Science ®Google Scholar
• Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369:1731 - 41; http://dx.doi.org/10.1016/S0140-6736(07)60780-6; PMID: 17512858
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118 - 21; PMID: 11719439
   PubMed Web of Science ®Google Scholar
• van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005; 104:1781 - 8; http://dx.doi.org/10.1002/cncr.21419; PMID: 16136600
   PubMed Web of Science ®Google Scholar
• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008; 3:557 - 86; http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.151538; PMID: 18039140
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53:245 - 66; http://dx.doi.org/10.1111/j.1365-2559.2008.02977.x; PMID: 18312355
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24:4764 - 74; http://dx.doi.org/10.1200/JCO.2006.06.2265; PMID: 16954519
   PubMed Web of Science ®Google Scholar
• Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011; 67:Suppl 1 S15 - 24; http://dx.doi.org/10.1007/s00280-010-1513-8; PMID: 21181476
   PubMedGoogle Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al, EORTC Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093 - 103; http://dx.doi.org/10.1016/j.ejca.2006.01.030; PMID: 16624552
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329 - 38; http://dx.doi.org/10.1016/S0140-6736(06)69446-4; PMID: 17046465
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26:5352 - 9; http://dx.doi.org/10.1200/JCO.2007.15.7461; PMID: 18955458
   PubMed Web of Science ®Google Scholar
• Sambol EB, Ambrosini G, Geha RC, Kennealey PT, Decarolis P, O’connor R, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006; 66:5858 - 66; http://dx.doi.org/10.1158/0008-5472.CAN-05-2933; PMID: 16740725
   PubMed Web of Science ®Google Scholar
• Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103:1078 - 84; http://dx.doi.org/10.1182/blood-2003-07-2477; PMID: 14551138
   PubMed Web of Science ®Google Scholar
• Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66:9153 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-06-0165; PMID: 16982758
   PubMed Web of Science ®Google Scholar
• Li CF, Huang WW, Wu JM, Yu SC, Hu TH, Uen YH, et al. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 2008; 14:7822 - 31; http://dx.doi.org/10.1158/1078-0432.CCR-08-1369; PMID: 19047110
   PubMed Web of Science ®Google Scholar
• Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009; 15:9 - 14; http://dx.doi.org/10.1158/1078-0432.CCR-08-0132; PMID: 19118027
   PubMed Web of Science ®Google Scholar
• Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 1996; 10:705 - 12; http://dx.doi.org/10.1210/me.10.6.705; PMID: 8776730
   PubMed Web of Science ®Google Scholar
• Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998; 16:2639 - 45; http://dx.doi.org/10.1038/sj.onc.1201790; PMID: 9632140
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68:3077 - 80, discussion 3080; http://dx.doi.org/10.1158/0008-5472.CAN-07-3293; PMID: 18451130
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407 - 10; http://dx.doi.org/10.1038/nature01913; PMID: 14508491
   PubMed Web of Science ®Google Scholar
• Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 2004; 11:787 - 97; http://dx.doi.org/10.1016/j.chembiol.2004.04.008; PMID: 15217612
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004; 3:551 - 66; PMID: 15141013
   PubMed Web of Science ®Google Scholar
• Banerji U, O’Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23:4152 - 61; http://dx.doi.org/10.1200/JCO.2005.00.612; PMID: 15961763
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23:1078 - 87; http://dx.doi.org/10.1200/JCO.2005.09.119; PMID: 15718306
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 2010; 16:3795 - 804; http://dx.doi.org/10.1158/1078-0432.CCR-10-0503; PMID: 20525756
   PubMed Web of Science ®Google Scholar
• Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, et al. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 2005; 4:138 - 41; http://dx.doi.org/10.3816/CGC.2005.n.024; PMID: 16197617
   PubMedGoogle Scholar
• Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006; 24:543 - 6; http://dx.doi.org/10.1007/s10637-006-9208-z; PMID: 16832603
   PubMed Web of Science ®Google Scholar
• Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008; 14:8302 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-1002; PMID: 19088048
   PubMed Web of Science ®Google Scholar
• Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998; 58:2385 - 96; PMID: 9622079
   PubMed Web of Science ®Google Scholar
• Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91:1940 - 9; http://dx.doi.org/10.1093/jnci/91.22.1940; PMID: 10564678
   PubMed Web of Science ®Google Scholar
• Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008; 51:196 - 218; http://dx.doi.org/10.1021/jm701018h; PMID: 18020435
   PubMed Web of Science ®Google Scholar
• Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther 2011; 10:1897 - 908; http://dx.doi.org/10.1158/1535-7163.MCT-11-0148; PMID: 21825009
   PubMed Web of Science ®Google Scholar
• Floris G, Sciot R, Wozniak A, Van Looy T, Wellens J, Faa G, et al. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res 2011; 17:5604 - 14; http://dx.doi.org/10.1158/1078-0432.CCR-11-0562; PMID: 21737509
   PubMed Web of Science ®Google Scholar
• Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol 2008; 36:1266 - 77; http://dx.doi.org/10.1016/j.exphem.2008.05.001; PMID: 18657349
   PubMed Web of Science ®Google Scholar
• Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000; 92:242 - 8; http://dx.doi.org/10.1093/jnci/92.3.242; PMID: 10655441
   PubMed Web of Science ®Google Scholar
• Demetri GD, Le Cesne A, von Mehren M, Chmielowski B, Bauer S, Chow WA, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. [abstract]. In: Proceedings of the ASCO Gastrointestinal Cancers Symposium; 2010 Jan 22–24; Orlando, FL. Alexandria (VA): ASCO; 2010. Abstract nr 64.
   Google Scholar
• Demetri GD, Heinrich MC, Chmielowski B, Morgan JA, George S, Bradley R, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. J Clin Oncol 2011; 29:Suppl abstr 10011
   Google Scholar
• Ide S, Motwani M, Jensen MR, Wang J, Huseinovic N, Stiegler P, et al. Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. J Clin Oncol 2009; 29:Suppl abstr 3533
   Google Scholar
• Willis MS, Townley-Tilson WH, Kang EY, Homeister JW, Patterson C. Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 2010; 106:463 - 78; http://dx.doi.org/10.1161/CIRCRESAHA.109.208801; PMID: 20167943
   PubMed Web of Science ®Google Scholar
• Kraft C, Peter M, Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol 2010; 12:836 - 41; http://dx.doi.org/10.1038/ncb0910-836; PMID: 20811356
   PubMed Web of Science ®Google Scholar
• Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 2005; 280:23727 - 34; http://dx.doi.org/10.1074/jbc.M503326200; PMID: 15845543
   PubMed Web of Science ®Google Scholar
• Olzmann JA, Chin LS. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 2008; 4:85 - 7; PMID: 17957134
   PubMed Web of Science ®Google Scholar
• Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447:859 - 63; http://dx.doi.org/10.1038/nature05853; PMID: 17568747
   PubMed Web of Science ®Google Scholar
• Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603 - 14; http://dx.doi.org/10.1083/jcb.200507002; PMID: 16286508
   PubMed Web of Science ®Google Scholar
• Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131 - 45; http://dx.doi.org/10.1074/jbc.M702824200; PMID: 17580304
   PubMed Web of Science ®Google Scholar
• Lamark T, Johansen T. Autophagy: links with the proteasome. Curr Opin Cell Biol 2010; 22:192 - 8; http://dx.doi.org/10.1016/j.ceb.2009.11.002; PMID: 19962293
   PubMed Web of Science ®Google Scholar
• Weidberg H, Shvets E, Elazar Z. Biogenesis and cargo selectivity of autophagosomes. Annu Rev Biochem 2011; 80:125 - 56; http://dx.doi.org/10.1146/annurev-biochem-052709-094552; PMID: 21548784
   PubMed Web of Science ®Google Scholar
• Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ 2012; •••; http://dx.doi.org/10.1038/cdd.2012.72; PMID: 22722335
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5:726 - 34; http://dx.doi.org/10.1038/nrc1692; PMID: 16148885
   PubMed Web of Science ®Google Scholar
• Isakson P, Bjørås M, Bøe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010; 116:2324 - 31; http://dx.doi.org/10.1182/blood-2010-01-261040; PMID: 20574048
   PubMed Web of Science ®Google Scholar
• Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy 2011; 7:401 - 11; http://dx.doi.org/10.4161/auto.7.4.14397; PMID: 21187718
   PubMed Web of Science ®Google Scholar
• Shen S, Zhang P, Lovchik MA, Li Y, Tang L, Chen Z, et al. Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J Cell Biol 2009; 185:629 - 39; http://dx.doi.org/10.1083/jcb.200810183; PMID: 19433452
   PubMed Web of Science ®Google Scholar
• Ou WB, Zhu MJ, Demetri GD, Fletcher CD, Fletcher JA. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene 2008; 27:5624 - 34; http://dx.doi.org/10.1038/onc.2008.177; PMID: 18521081
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 2007; 12:719 - 26; http://dx.doi.org/10.1634/theoncologist.12-6-719; PMID: 17602061
   PubMed Web of Science ®Google Scholar
• Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011; 67:Suppl 1 S25 - 43; http://dx.doi.org/10.1007/s00280-010-1526-3; PMID: 21116624
   PubMed Web of Science ®Google Scholar
• Warrens AN, Jones MD, Lechler RI. Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene 1997; 186:29 - 35; http://dx.doi.org/10.1016/S0378-1119(96)00674-9; PMID: 9047341
   PubMed Web of Science ®Google Scholar
• Chen KL, Chang WS, Cheung CH, Lin CC, Huang CC, Yang YN, et al. Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Lett 2012; 317:89 - 98; http://dx.doi.org/10.1016/j.canlet.2011.11.015; PMID: 22101325
   PubMed Web of Science ®Google Scholar
• Finlay GJ, Baguley BC, Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984; 139:272 - 7; http://dx.doi.org/10.1016/0003-2697(84)90002-2; PMID: 6476363
   PubMed Web of Science ®Google Scholar